Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide begins suppressing appetite within the first one to two weeks of starting treatment for most people, though the full effect builds gradually over several months as the dose increases. The appetite-reducing action comes from semaglutide's work on GLP-1 receptors in the brain and gut — slowing gastric emptying, reducing hunger signals and increasing feelings of fullness after smaller meals. These are prescription-only medicines: a GPhC-registered prescriber assesses whether Wegovy is clinically suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The 0.25mg starting dose is there to let your body adjust, not to deliver maximum effect. Even so, many people notice something in the first week or two: meals that used to finish without a second thought now feel like enough partway through, or the mid-morning snack craving simply doesn't arrive. The NHS medicines page for semaglutide describes the mechanism clearly, it activates GLP-1 receptors that slow how quickly the stomach empties and that communicate directly with appetite centres in the brain.
Not everyone feels this at 0.25mg. If you reach the end of the first month and think nothing has changed, that is completely normal. The starting dose is a tolerability measure, and the meaningful appetite shift usually comes later. Some people find the nausea they experience in week one is the only obvious signal that something is happening at all, the hunger reduction follows.
It can feel frustrating to be a few weeks in with no clear result, and if you want a clearer sense of the expected timeline, our page on when appetite suppression typically starts with semaglutide explains what to look out for at each stage. That frustration is understandable, and it is worth knowing the dose trajectory is deliberate, the treatment is designed to build, not to hit hard at the start.
Each four-week step up the titration schedule (0.25mg to 0.5mg, then 1.0mg, then 1.7mg) tends to bring a more noticeable reduction in appetite than the previous one. This is the phase most people describe as the real shift: portions shrink naturally, feelings of hunger between meals fade, and high-calorie foods that used to be hard to resist become easier to leave. Gastric emptying slows further with each dose increase, so meals physically take longer to digest, which extends the sensation of fullness.
This is also the phase where what you eat starts to matter more than it did before, because appetite suppression works best alongside a reduced-calorie diet. Our guide to what to eat on Wegovy covers practical food choices that support the treatment without making you feel deprived. Protein, fibre and hydration become especially relevant here, the prescriber and any dietitian you work with are the right people to shape a personal plan.
Side effects during dose increases are typically gastrointestinal: nausea, indigestion, loose stools. They are most common in the days after a step-up and usually settle within a week or two. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at 2.4mg, evidence that the appetite suppression is meaningful and sustained at maintenance dose.
At 2.4mg, the licensed maintenance dose of Wegovy, appetite suppression reaches its most consistent level. For most people on Wegovy, this means eating less without a constant effort of willpower, hunger arrives less frequently and passes more quickly when it does. Cravings for very rich or fatty food also tend to reduce, partly because gastric emptying remains slowed and partly through central appetite pathways.
The MHRA approved a higher 7.2mg maintenance dose in January 2026, with trials reporting around 20.7% average weight loss at that level. Whether a higher dose is appropriate is a clinical decision, something a prescriber discusses based on how you have responded so far. If you feel Wegovy's appetite effect has faded or stopped working at your current dose, it is worth reading more about what to do when Wegovy no longer suppresses appetite before drawing conclusions; there are several reasons this can happen, and most are addressable.
A note on realistic expectations: semaglutide suppresses appetite, it does not eliminate it. Hunger will still arrive, it simply arrives less insistently, and fullness comes sooner. That is the mechanism, and it works best when paired with the lifestyle changes your prescriber supports you with throughout treatment.
The timing varies between individuals, and several factors influence it. People who are very sensitive to GLP-1 effects sometimes notice appetite changes within days of the first injection. Others, particularly at the lower starting doses, notice very little until the second or third titration step. Current dose, time on treatment and individual physiology all play a part.
If you are considering Wegovy or have just started and want a clearer sense of what the treatment involves, the Wegovy overview page covers the full picture, from how it works to eligibility and what private access involves. For those wondering whether appetite suppression is actually happening when it feels subtle, our page on how Wegovy suppresses appetite goes into the mechanism in more depth.
If you are already on treatment and feel the appetite effect has disappeared, that is a different concern worth discussing with a prescriber. Our page on Wegovy not suppressing appetite covers the common reasons and what can be done. The right support during treatment makes a real difference, and if you have not yet started, speaking to our prescribers is a sensible first step before comparing doses and timelines in the abstract.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.